Working… Menu

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04914117
Recruitment Status : Recruiting
First Posted : June 4, 2021
Last Update Posted : November 10, 2021
Information provided by (Responsible Party):
RemeGen Co., Ltd.

Brief Summary:
This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).

Condition or disease Intervention/treatment Phase
Unresectable Solid Tumor Metastatic Solid Tumor Locally Advanced Solid Tumor Drug: RC118 for injection Phase 1

Detailed Description:
This is an open-label, Phase 1, FIH, study consisting of dose-escalation (Part A) and dose confirmation (Part B) in Australia. This trial is to evaluate the safety, tolerability (MTD/MAD), PK, immunogenicity of RC118, and further determine the RP2D. In addition, the preliminary anti-tumour efficacy of RC118 as single agent will be assessed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 33 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Estimated Study Start Date : December 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : February 2022

Arm Intervention/treatment
Experimental: RC118 for injection

Part A (Dose Escalation): RC118 will be administered through IV infusion at the various dose levels, including 0.25, 0.5, 1.0, 1.5, 2, 2.5, and 3 mg/kg, 1-12 subjects for each dose level.

Part B (Dose Confirmation): RC118 will be administered at up to two dose levels, which is equal or lower than MTD/MAD, through IV infusion. Each dose level contains 3-6 subjects.

Drug: RC118 for injection
RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.

Primary Outcome Measures :
  1. MTD/MAD based on number of dose-limiting toxicities (DLTs) [ Time Frame: Up to 18 months ]
    The maximum tolerated dose (MTD)/maximum administered dose (MAD) will be assessed based on the number of patients experiencing DLTs, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. If the MTD cannot be reached in this study, the MAD will be recorded.

  2. Determine Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 18 months ]
    The RP2D may be selected based on the MTD/MAD following consultation with the safety monitoring committee with all available data.

  3. Adverse Events [ Time Frame: Up to 18 months ]
    The adverse events occurring or worsening on or after the first dose of the study drug will be recorded.

Secondary Outcome Measures :
  1. Object Response Rate (ORR) [ Time Frame: Up to 18 months ]
    ORR will be determined according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. The ORR is defined as the number of patients are either complete response (CR) or partial response (PR), relative to the number of patients belonging to the study of interest.

  2. Progression Free Survival (PFS) [ Time Frame: Up to 18 months ]
    PFS is defined as the time from the date of first administration to the date of the first documentation of progressive disease or death due to any cause, whichever occurs first.

  3. Disease Control Rate (DCR) [ Time Frame: Up to 18 months ]
    DCR is the proportion of patients with disease control.

  4. Duration of response (DOR) [ Time Frame: Up to 18 months ]
    DOR is defined, for patients with response, as the time from first documentation of response (CR or PR) to the date of first documentation of progression of disease or death due to any causes whichever occurs first.

  5. Immunogenicity [ Time Frame: Up to 18 months ]
    Incidence of anti-drug antibody (ADA) against RC118

  6. Maximum Plasma Concentration [Cmax] [ Time Frame: Up to 18 months ]
    Cmax of total antibodies, RC118 and free MMAE

  7. Area under the plasma concentration [AUC] [ Time Frame: Up to 18 months ]
    AUC of total antibodies, RC118 and free MMAE

  8. Tmax [ Time Frame: Up to 18 months ]
    Peak time (Tmax) of total antibodies, RC118 and free MMAE

Other Outcome Measures:
  1. CLDN18.2 expression [ Time Frame: Up to 18 months ]
    The expression of CLDN18.2 will be scored semi-quantitatively, based on staining intensity and the percentage of staining in provided archived/biopsy tumor samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be able to provide documented voluntary informed consent.
  2. Male or female patient ≥ 18 years and ≤ 75 years.
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0 or 1.
  4. The expected survival period exceeds 12 weeks.
  5. At least one target lesion that can be measured per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
  6. Histologically documented, incurable, unresectable locally advanced or metastatic tumours that are intolerable or refractory to standard therapies.
  7. Patients agree to provide pre-treatment archived /biopsy tumour samples for retrospective Claudin 18.2 test. Archival tumour tissue should be from the most recent timepoint before entering the trial. In addition, archived samples obtained out of the screening are acceptable if it is discussed and approved by the Investigator and Sponsor in advance. Only when archived samples cannot be obtained, the biopsy will be considered at screening. Fresh tumour biopsies will NOT be considered if significant risk procedures are required with the discretion of Investigator.
  8. Adequate bone marrow, liver, and renal function defined as: absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet ≥ 100 × 109/L, haemoglobin ≥ 90 g/L, serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), ALT, AST or ALP ≤ 2.5 × ULN (≤ 5 × ULN when there is known liver metastasis), serum creatinine ≤ 1.5 × ULN, INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN.
  9. Willingness to avoid pregnancy or fathering children based on the criteria below:

    • Female patients of childbearing potential and male patients with partners of childbearing potential treated with RC118, must agree to use a highly effective form(s) of contraception during study and within 6 months after the last dose. Those methods include but not limited to combined (oestrogen and progestogen containing) hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.
    • Females of non-childbearing potential (e.g., surgically sterile with a hysterectomy and/or bilateral oophorectomy or chemically sterile or ≥ 12 months of amenorrhea in the absence of chemotherapy, anti-oestrogens, or ovarian suppression). Those females do not need to undergo pregnancy test.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Diagnosed active hepatitis B infection (defined as presence of hepatitis B surface Ag and/or hepatitis B DNA), active hepatitis C infection (defined as presence of hepatitis C RNA), and human immunodeficiency virus infection (defined as positive HIV test) during the screening period.
  3. Received vaccines within 4 weeks prior to administration or plan on receiving any vaccine during the study.
  4. Subjects with a history of other acquired/congenital immunodeficiency diseases or organ transplantation.
  5. Patients have history of targeted therapy of Claudins, or participated in other clinical trials and received investigational product within 4 weeks before the first administration of study drug.
  6. Allergic constitution or allergic to known research drug active ingredients or excipient.
  7. Patients who are under the treatment of anticoagulant drugs (e.g., warfarin, apixaban, and heparin). Patients using prophylactic doses of heparin (e.g., LMWH) is eligible in the study.
  8. Patients undergoing any anti-tumour therapy, including surgery, chemotherapy, radiotherapy and biological therapy, within 4 weeks prior to the first administration of study drug, or palliative radiotherapy for bone/other solitary metastases within 2 weeks prior to the first administration of study drug.
  9. Previous adverse reactions resulting from previous anti-tumour therapies, which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia) at screening.
  10. There are clinical symptoms of fluid in the third space (e.g., large amounts of pleural fluid or ascites) that cannot be controlled by drainage or other therapies.
  11. A clinically significant active infection judged by the investigator.
  12. Comorbidities that may seriously endanger the patient's safety or affect the completion of the study, such as gastrointestinal bleeding (within 4 weeks prior to the screening period), peptic ulcer, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, kidney failure, and uncontrolled diabetes.
  13. QTc interval > 480 ms in both male and female (based on the mean value of the triplicate screening ECGs); family or personal history of long/short QT syndrome, History of ventricular arrhythmia deemed clinically significant by the investigator, or currently receiving antiarrhythmic drug treatment, or implantation of arrhythmia defibrillation device.
  14. History of myocardial infarction within 6 months prior to the screening period, severe or unstable angina pectoris, coronary or peripheral artery bypass grafting, heart failure ≥ 3 (New York Heart Association), or uncontrolled hypertension.
  15. Patients with known current alcohol dependence or drug abuse.
  16. Patients with a long-term history of systemic steroid therapy. Patients with short-term (≤ 7 days) use and drug withdrawal > 2 weeks are eligible.
  17. History or presence of uncontrolled primary brain tumours (e.g., leptomeningeal carcinomatosis) or metastatic brain tumours, unless considered stable by the Investigator and local therapy was completed.
  18. History or presence of Grade ≥ 2 peripheral neuropathy.
  19. History or presence of uncontrolled mental illness at the discretion of the Investigator, which may place the participant at increased risk of safety/tolerability issues.
  20. The patient is, in the opinion of the investigator, expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements in the future.
  21. Patients who are not appropriate for this clinical trial at the discretion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04914117

Layout table for location contacts
Contact: Remegen Biosciences 1-301-284-1015

Layout table for location information
Australia, New South Wales
Remegen Site #12 Not yet recruiting
Macquarie Park, New South Wales, Australia, 2109
Australia, South Australia
Remegen Site #14 Not yet recruiting
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Remegen Site #13 Not yet recruiting
Frankston, Victoria, Australia, 3199
Remegen Site #11 Recruiting
Malvern, Victoria, Australia, 3144
Sponsors and Collaborators
RemeGen Co., Ltd.
Layout table for additonal information
Responsible Party: RemeGen Co., Ltd. Identifier: NCT04914117    
Other Study ID Numbers: RC118G001
First Posted: June 4, 2021    Key Record Dates
Last Update Posted: November 10, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms